TY - JOUR
T1 - Serum apolipoprotein B is associated with increased risk of metabolic syndrome among middle-aged and elderly Chinese
T2 - A cross-sectional and prospective cohort study
AU - Du, Rui
AU - Wu, Xueyan
AU - Peng, Kui
AU - Lin, Lin
AU - Li, Mian
AU - Xu, Yu
AU - Xu, Min
AU - Chen, Yuhong
AU - Li, Donghui
AU - Lu, Jieli
AU - Bi, Yufang
AU - Wang, Weiqing
AU - Ning, Guang
N1 - Funding Information:
This study was supported by grants from the Ministry of Science and Technology of the People's Republic of China (2016YFC1305202), The National Natural Science Foundation of China (81670795), the Shanghai Municipal Education Commission (15SG15, 20152202), and the Shanghai Sailing Program (18YF1419900). The funding agencies had no role in the design and conduct of the study, in the collection, management, analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript. The present study would not have been possible without the participation of the participants.
Funding Information:
Ministry of Science and Technology of the People's Republic of China, Grant/Award Number: 2016YFC1305202; National Natural Science Foundation of China, Grant/Award Number: 81670795; Shanghai Municipal Education Commission, Grant/Award Numbers: 15SG15, 20152202; Shanghai Sailing Program, Grant/ Award Number: 18YF1419900
Publisher Copyright:
© 2019 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd
PY - 2019
Y1 - 2019
N2 - Background: Serum apolipoprotein (apo) B has been associated with an increased risk of atherosclerotic cardiovascular diseases. However, findings on the association between apoB and the risk of metabolic syndrome (MetS) are inconsistent. The purpose of this study was to investigate the association between serum apoB and MetS risk in Chinese population. Methods: A baseline survey was conducted in a population-based cohort of 10 340 adults aged ≥40 years in Shanghai, China, in 2010. A follow-up visit was conducted to assess incident diabetes in 2015. Results: At baseline, 2794 of 10 340 participants (27.02%) had MetS. Serum apoB was significantly associated with an increased risk of prevalent MetS. Multivariable-adjusted odds ratios and 95% confidence intervals (CIs) for quintiles 2-5 compared with quintile 1 (reference) were 1.29 (1.02-1.63), 1.47 (1.18-1.84), 1.32 (1.06-1.65), and 2.02 (1.61-2.51), respectively (Ptrend < 0.05). During an average of 5.1 years follow-up, 4627 individuals without MetS at baseline showed a significant association between apoB and the risk of incident MetS. Multivariable-adjusted risk ratios (95% CIs) for subjects in apoB quintiles 2-5 compared with the reference were 1.43 (1.13-1.82), 1.57 (1.25-1.98), 1.74 (1.38-2.18), and 2.07 (1.66-2.58), respectively (Ptrend < 0.05). Stratified analysis suggested that the above association was much stronger among normal weight individuals than in those who were overweight or obese. Conclusion: These cross-sectional and prospective studies provide evidence that serum apoB is associated with existing MetS and is a possible predictor of the risk of MetS, especially among normal weight individuals.
AB - Background: Serum apolipoprotein (apo) B has been associated with an increased risk of atherosclerotic cardiovascular diseases. However, findings on the association between apoB and the risk of metabolic syndrome (MetS) are inconsistent. The purpose of this study was to investigate the association between serum apoB and MetS risk in Chinese population. Methods: A baseline survey was conducted in a population-based cohort of 10 340 adults aged ≥40 years in Shanghai, China, in 2010. A follow-up visit was conducted to assess incident diabetes in 2015. Results: At baseline, 2794 of 10 340 participants (27.02%) had MetS. Serum apoB was significantly associated with an increased risk of prevalent MetS. Multivariable-adjusted odds ratios and 95% confidence intervals (CIs) for quintiles 2-5 compared with quintile 1 (reference) were 1.29 (1.02-1.63), 1.47 (1.18-1.84), 1.32 (1.06-1.65), and 2.02 (1.61-2.51), respectively (Ptrend < 0.05). During an average of 5.1 years follow-up, 4627 individuals without MetS at baseline showed a significant association between apoB and the risk of incident MetS. Multivariable-adjusted risk ratios (95% CIs) for subjects in apoB quintiles 2-5 compared with the reference were 1.43 (1.13-1.82), 1.57 (1.25-1.98), 1.74 (1.38-2.18), and 2.07 (1.66-2.58), respectively (Ptrend < 0.05). Stratified analysis suggested that the above association was much stronger among normal weight individuals than in those who were overweight or obese. Conclusion: These cross-sectional and prospective studies provide evidence that serum apoB is associated with existing MetS and is a possible predictor of the risk of MetS, especially among normal weight individuals.
KW - apolipoprotein B
KW - lipids
KW - lipoprotein
KW - metabolic syndrome
KW - risk
UR - http://www.scopus.com/inward/record.url?scp=85061817254&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061817254&partnerID=8YFLogxK
U2 - 10.1111/1753-0407.12904
DO - 10.1111/1753-0407.12904
M3 - Article
C2 - 30652427
AN - SCOPUS:85061817254
SN - 1753-0393
VL - 11
SP - 752
EP - 760
JO - Journal of Diabetes
JF - Journal of Diabetes
IS - 9
ER -